All In Biotech

Drug Trial Radar · NCT05270863

Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia

Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia

Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Mar 30, 2022

Primary completion

Mar 17, 2023

Study completion Apr 10, 2023

Sponsor

Lead sponsor
Visus TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Conditions

  • Presbyopia

Interventions

  • BRIMOCHOL™ PFDrug

    A single drop in each eye at a visit.

  • Carbachol PFDrug

    A single drop in each eye at a visit.

  • Brimonidine tartrateDrug

    A single drop in each eye at a visit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual AcuityTime frame: Day 1 Hour 1

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Visus Therapeutics Investigative Site

    Glendale, California

  • Visus Therapeutics Investigative Site

    Rancho Cordova, California

  • Visus Therapeutics Investigative Site

    Jacksonville, Florida

  • Visus Therapeutics Investigative Site

    Morrow, Georgia

  • Visus Therapeutics Investigative Site

    Roswell, Georgia

  • Visus Therapeutics Investigative Site

    Shawnee Mission, Kansas

  • Visus Therapeutics Investigative Site

    Kansas City, Missouri

  • Visus Therapeutics Investigative Site

    Kansas City, Missouri

  • Visus Therapeutics Investigative Site

    Pittsburgh, Pennsylvania

  • Visus Therapeutics Investigative Site

    Memphis, Tennessee

  • Visus Therapeutics Investigative Site

    Memphis, Tennessee

  • Visus Therapeutics Investigative Site

    Cedar Park, Texas

  • Visus Therapeutics Investigative Site

    Houston, Texas

  • Visus Therapeutics Investigative Site

    San Antonio, Texas

  • Visus Therapeutics Investigative Site

    Ogden, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.